eHEALTH BureauVygon, a leading French Multinational, dealing in Catheters, launches its new range of Neonatal PICC (Peripherally inserted central catheters) Lines in the Indian market. This range has been designed to reduce trauma, morbidity and consequent infant mortality. A peripherally inserted central catheter (PICC line) is a form of intravenous access that can be used for a prolonged period of time. It is an alternative to conventional intravenous access devices like the cannula. A cannula causes the baby a lot of trauma, blood loss and exposes him to greater risk of infections and other dangers. Vygon PICC lines can substantially reduce the trauma, morbidity and consequent infant mortality.Alan Martin, International Training Director Vygon France, said “This illustrates Vygon’s commitment to enhance Neonatal Vascular Access care on a global basis. I have worked in India as a theatre  technician and I recognise the wealth of clinical talent in India. By bringing this range to India we wish to give the talented Indian Neonatologist with what we think is the best product today, resulting in improved care of the neonates.”Pavan Choudary, Managing Director of Vygon India Pvt. Ltd commented, “Conventional Intravenous access devices like cannula cause a lot of trauma to the baby. This trauma almost always increases the blood pressure of the baby as well as causes oxygen desaturation and exposes the baby to other dangers thus putting the baby’s life at risk. Vygon’s neonatal range is an answer to this serious problem which neonatologist’s face and we will take this answer to every neonatologist of the country.”Vygon plans to expose neonatologist all over India to these products by conducting various workshops starting from Delhi NCR Neonatologists and is expecting a big difference in trauma, morbidity and as a consequence in infant mortality rate by use of these products.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.